Labor Market Pulse · Life Sciences · September 2026
Life Sciences Labor Market Report: Hagerstown-Martinsburg, MD-WV MSA — September 2026
Maryland biotech layoffs are filling Hagerstown's talent gap.
Washington County's 4.8% jobless rate and Maryland's 1,200+ bioscience layoffs are pushing regulatory and manufacturing talent toward Hagerstown, even as local Lab Technician pay jumps to $66,200 against a falling national median.
Free archive edition. Published by WageScape as sent to subscribers; data as of September 2026.
Key indicators
- Washington County unemployment: 4.8% — vs 4.0% Hagerstown-Martinsburg MSA, March 2026
- Maryland bioscience layoffs: 1,200+ — Past 12 months, GSK, REGENXBIO, MacroGenics
- Lab Technician advertised pay, metro: $66,200 — vs $47,402 national, which is declining
- Maryland statewide WARN-affected workers: 6,538 — Down 48% from 2025, 96 notices in 2026
Key takeaways
Maryland's bioscience layoffs are Hagerstown's hiring opportunity.
Over 1,200 bioscience layoffs statewide in the past 12 months, concentrated at GSK, REGENXBIO, and MacroGenics, are pushing experienced regulatory and manufacturing talent into secondary labor markets. Leaders filling CMC or quality roles may find candidate quality improving faster than advertised pay is rising locally.
Clinical Research Associate pay is climbing faster locally than it typically would.
Metro CRA pay sits at $81,282 against a national median of $90,956, both trending up significantly — a narrowing gap that suggests Hagerstown employers are competing harder to retain clinical staff rather than losing them to larger markets. This compresses the traditional discount metro employers could expect against DC-area or Boston pay scales.
Lab Technician pay is diverging sharply from the national trend.
Metro Lab Technician pay rose significantly to $66,200 while the national median fell to $47,402 — a reversal that may reflect tighter local supply following consolidation at nearby pharma and biotech sites. Benchmarking this role against national survey data alone would understate what it now costs to fill locally.
Federal research cuts are reshaping who is available, not just how many.
HHS reductions from 82,000 to 62,000 positions are releasing scientists and regulatory staff with federal-adjacent experience into regional markets, including corridors feeding Hagerstown-Martinsburg. This shifts workforce planning from a pure pay question to a credentials-matching question — screening for regulatory pathway experience may matter more than base pay competitiveness this quarter.
Median advertised pay by role — Hagerstown-Martinsburg, MD-WV MSA
| Role | 25th percentile | Median advertised pay | 75th percentile | Metro trend | National median |
|---|---|---|---|---|---|
| Research Scientist * | $99,000 | $120,000 | $130,000 | Moderate increase | $131,354 |
| Clinical Research Associate * | $61,907 | $81,282 | $98,256 | Significant increase | $90,956 |
| Lab Technician | $46,718 | $66,200 | $66,200 | Significant increase | $47,402 |
| Regulatory Affairs Specialist * | $84,940 | $124,261 | $130,578 | Significant increase | $104,000 |
| Clinical Data Manager * | $96,686 | $123,706 | $135,775 | Moderate increase | $123,031 |
| Biostatistician * | $93,891 | $119,130 | $132,848 | Moderate increase | $133,322 |
| Validation Engineer * | $98,963 | $116,464 | $126,491 | Significant increase | $108,377 |
* State-level figure shown where metro postings were too few.
WageScape's median is calibrated to correct for spurious low-value postings (reported as the 60th percentile of raw advertised pay). Download: CSV · JSON
Local market conditions
Washington County unemployment sits at 4.8% versus the MSA's 4.0% reading, a gap that reflects Maryland's broader bioscience contraction — GSK's Shady Grove closure, REGENXBIO's 15% reduction, and MacroGenics' workforce cuts are pushing credentialed regulatory and manufacturing talent toward secondary metros like Hagerstown-Martinsburg. Federal HHS headcount reductions from 82,000 to 62,000 are compounding this supply shift, sending experienced clinical and regulatory professionals into a labor pool that local Life Sci employers can now tap at lower acquisition cost than six months ago.
What it means
Displaced talent from I-270 corridor consolidations creates a near-term sourcing opportunity for Hagerstown-area quality, manufacturing, and regulatory roles that previously required premium pay to pull candidates out of the DC/Frederick bioscience cluster. This same dynamic complicates build-vs-outsource math: CDMOs absorbing displaced capacity may offer faster scale-up than internal hires, even as available talent makes internal builds look more attractive on cost. Consider reviewing regulatory and CMC req pipelines now to capture candidates exiting GSK, REGENXBIO, and MacroGenics before competing employers in Frederick or Montgomery County do.
Looking ahead
Worth watching: Washington County's 4.8% unemployment rate, nearly a full point above the MSA's 4.0% reading, may tighten or loosen further as displaced Maryland bioscience workers decide whether to commute or relocate. Track whether local applicant volume for regulatory and quality postings increases through October.
Emerging pressure point: GSK's Shady Grove closure completes by March 2026, and the resulting wave of regulatory and R&D talent entering the market has not yet fully materialized locally. Leaders with open CMC or regulatory affairs reqs should expect candidate flow to build over the next 60 days.
Potential inflection point: Biostatistician pay nationally ($133,322) continues outpacing the metro figure ($119,130) despite both trending up moderately — a gap that could widen if remote-eligible biostatistics roles pull Hagerstown-based talent toward national employers paying coastal rates for remote work.
Early indicator: Statewide WARN-covered layoffs dropped 48% year over year in affected-worker count, suggesting Maryland's bioscience contraction may be stabilizing rather than accelerating. Confirm this holds before assuming continued inbound talent supply for Hagerstown-area openings.
Methodology
Advertised pay from active employer job postings, not survey data. WageScape's median is calibrated to correct for spurious low-value postings: distribution analysis shows roughly the lowest 10% of raw values are erroneous entries, so the reported median is the 60th percentile of raw advertised pay. WageScape observes 98% of U.S. job openings daily.
Free to read and cite with attribution to WageScape. Terms of use.